BIOIMPACT CAPITAL LLC
Q2 2023 Form 13-F

BOSTON, MASSACHUSETTS
CIK 0001687078 · CRD 309865 · SEC-registered investment adviser
$496.6M Reported Value Total

BIOIMPACT CAPITAL LLC reports 9 total accounts under management (AUM). There are 9 discretionary accounts valued at $1,986,654,826, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
4 funds · $2.0B gross asset value
Other: $1.8B · Hedge Fund: $138.3M
Source: Form ADV filed 2022-11-17
Reported value
$496.6M
Quarter over quarter
+13.2%
Holdings
34
Top-10 concentration
64.9%

Key People

Form ADV owners & control persons
Christiana Goh Bardon
MANAGING MEMBER
Luke Basil Evnin
MEMBER
Ansbert K Gadicke
MANAGING MEMBER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2023 13F record

Q2 2023 13F filing summary

Q2 2023 Form 13F portfolio summary
Period of report June 30, 2023
Filed August 14, 2023
Form 13F-HR
Reported value $496.6M
Positions 34
Change in reported value +29.0%
New positions 10
Exited positions 7
Position turnover 41.5%
Top-10 concentration 64.9%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
37 $1.6B
Q1 2026 13F
Filed May 15, 2026
41 $1.3B
Q4 2025 13F
Filed Feb 17, 2026
38 $874.0M
Q3 2025 13F
Filed Nov 14, 2025
40 $610.9M
Q2 2025 13F
Filed Aug 14, 2025
44 $577.2M
Q1 2025 13F
Filed May 15, 2025
43 $581.7M
Q4 2024 13F
Filed Feb 14, 2025
47 $704.4M
Q3 2024 13F
Filed Nov 13, 2024
43 $666.6M
Q2 2024 13F
Filed Aug 14, 2024
44 $643.5M
Q1 2024 13F
Filed May 15, 2024
38 $622.0M
Q4 2023 13F
Filed Feb 13, 2024
32 $427.4M
Q3 2023 13F
Filed Nov 14, 2023
32 $374.6M
Q2 2023 13F
Filed Aug 14, 2023
34 $496.6M
Q1 2023 13F
Filed May 12, 2023
31 $384.9M
Q4 2022 13F
Filed Feb 14, 2023
33 $385.5M
Q3 2022 13F
Filed Nov 14, 2022
38 $422.2M
Q2 2022 13F
Filed Aug 11, 2022
37 $360.0M
Q1 2022 13F
Filed May 13, 2022
37 $372.6M
Q4 2021 13F
Filed Feb 11, 2022
33 $548.5M
Q3 2021 13F
Filed Nov 15, 2021
33 $644.7M

7 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q2 2023

Largest Q2 2023 13F positions by reported value
# Holding Reported value % of portfolio
1 CGEM Cullinan Oncology, Inc. $82.3M 16.57%
2 ISEE Iveric Bio Inc $47.8M 9.62%
3 KDNY Chinook Therapeutics, Inc. $38.6M 7.76%
4 GERN Geron Corporation $29.5M 5.94%
5 RETA Reata Pharmaceuticals, Inc. $23.9M 4.81%
6 ITOS iTeos Therapeutics, Inc. $23.1M 4.65%
7 NTLA Intellia Therapeutics, Inc. $22.2M 4.47%
8 IOVA Iovance Biotherapeutics Inc $20.8M 4.18%
9 RPTX Repare Therapeutics, Inc. $17.3M 3.49%
10 RLAY Relay Therapeutics Inc. $17.0M 3.43%
11 VERV Verve Therapeutics, Inc $16.1M 3.24%
12 MLTX Moonlake Immunotherapeutics $15.1M 3.03%
13 RGNX REGENXBIO Inc. $13.1M 2.64%
14 KRTX Karuna Therapeutics Inc $11.6M 2.33%
15 INSM Insmed Incorporated $11.2M 2.25%
16 XERS Xeris Biopharma Holdings Inc $10.4M 2.1%
17 MDGL Madrigal Pharmaceuticals inc $8.8M 1.77%
18 CRNX Crinetics Pharmaceuticals Inc. $8.6M 1.74%
19 TVTX Travere Therapeutics Inc. $8.5M 1.71%
20 RVMD Revolution Medicines, Inc. $7.3M 1.47%

Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings